Denne part fremførte endvidere, at importen i UP af celler fra andre tredjelande lå på samme prisniveau som importen fra Kina, men fik endnu større markedsandele svarende til EU-erhvervsgrenens tab af markedsandele.
This party argued further that, as regards the IP, imports of cells from other third countries were at the same price level as Chinese imports but gained more market share corresponding to the loss of market share of the Union industry.